Sign In
Buy PACB
$1.15
-0.0350 (-2.95%)
At Close: Aug 10, 2026
PacBio Completes Sale of Short-Read Sequencing Assets
09:05am, Monday, 02'nd Feb 2026
MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of se
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of “Hold” from Analysts
04:24am, Monday, 02'nd Feb 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) has been given an average recommendation of "Hold" by the seven brokerages that are presently covering the company, MarketBeat
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
07:15pm, Friday, 30'th Jan 2026
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $2.26, indicating a -4.64% shift from the previous trading day.
PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation
12:16pm, Wednesday, 28'th Jan 2026
Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving margin improvements. Non-GAAP gross margin hit 42% in Q3, with management att
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
04:05pm, Tuesday, 27'th Jan 2026
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial r
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts
07:15pm, Friday, 23'rd Jan 2026
Pacific Biosciences of California (PACB) closed the most recent trading day at $2.58, moving 3.37% from the previous trading session.
PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research
11:36am, Thursday, 15'th Jan 2026
PACB stock jumps as HiFi whole-genome sequencing becomes first-line in major SUDC research, highlighting adoption momentum.
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:55pm, Monday, 12'th Jan 2026
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models The planned collaboration highlights the role of complete genome resolution in scaling
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
09:05am, Monday, 12'th Jan 2026
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio's Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families Trios from 200 families
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
12:21pm, Friday, 09'th Jan 2026
PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.
Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material Community-developed approach combines multi-contact 3C
Here's Why You Should Add PacBio Stock to Your Portfolio
01:10pm, Wednesday, 07'th Jan 2026
PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.
Three Genomics Stocks Worth Tracking This Year
08:11am, Tuesday, 06'th Jan 2026
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
12:23pm, Monday, 05'th Jan 2026
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
